Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10376463 Ocular iontophoretic delivery of dexamethasone and formulations thereof

Patent 10376463 was granted and assigned to EyeGate Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

EyeGate Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10376463

Patent Inventor Names

Michael A. Patane0

Mike Jaffe0

Gary Cook0

Perry Calias0

Date of Patent

August 13, 2019

Patent Application Number

13469481

Date Filed

May 11, 2012

Patent Citations Received

‌

US Patent 11872206 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11559509 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11576890 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11617735 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11858909 Deuterated etoricoxib, methods of manufacture, and use thereof

Patent Primary Examiner

‌

Marcos L Sznaidman

Patent abstract

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10376463 Ocular iontophoretic delivery of dexamethasone and formulations thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API